title: Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.
abstract: We examined the feasibility of brief outpatient detoxification as a treatment for prescription opioid (PO) abusers. Fifteen PO-dependent adults were enrolled to receive buprenorphine stabilization, a 2-week buprenorphine taper, and subsequent naltrexone for those who completed the taper. Subjects also received behavioral therapy, urinalysis monitoring, and double-blind drug administration. Subjects provided 83.8%, 91.7% and 31.2% opioid-negative samples during stabilization, taper and naltrexone phases, respectively. Inspection of individual subject data revealed systematic differences in whether subjects successfully completed the taper without resumption of illicit opioid use. Post-hoc analyses were used to examine the characteristics of subjects who successfully completed the taper (Responders, n=5) vs. those who failed to do so (Nonresponders, n=9). These pilot data suggest a subset of PO abusers may respond to brief buprenorphine detoxification, though future efforts should aim to improve outcomes, investigate individual differences in treatment response and identify characteristics that may predict those for whom longer-term agonist treatment is warranted.
authors.affiliation: Department of Psychiatry, University of Vermont, United States. stacey.sigmon@uvm.edu
authors.forename: Stacey C
authors.initials: SC
authors.lastname: Sigmon
authors.forename: Kelly E
authors.initials: KE
authors.lastname: Dunn
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Badger
authors.forename: Sarah H
authors.initials: SH
authors.lastname: Heil
authors.forename: Stephen T
authors.initials: ST
authors.lastname: Higgins
mesh_terms: D000328:Adult; D001521:Behavior Therapy; D002047:Buprenorphine / Q000627:therapeutic use*; D004812:Epidemiologic Methods; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D009271:Naltrexone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000534:rehabilitation* / Q000652:urine; D055553:Prescription Drugs / Q000009:adverse effects*; D015813:Substance Abuse Detection; D013997:Time Factors
chemical_list: D009292:Narcotic Antagonists; D055553:Prescription Drugs; D002047:Buprenorphine; D009271:Naltrexone